Latest News for: kers

Edit

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in ...

Nasdaq Globe Newswire 31 Mar 2025
... of proteins, today announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers.
Edit

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers (Form 8-K) (Keros Therapeutics Inc)

Public Technologies 31 Mar 2025
) Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers ... •Keros plans on advancing KER-065 into a Phase 2 clinical trial in DMD, subject to positive regulatory interaction ... About KER-065.
Edit

KER-065 Data Update (Keros Therapeutics Inc)

Public Technologies 31 Mar 2025
KER-065 Update ... KER-065.  KER-065 is an investigational modified activin receptor IIA (ActRIIA) and activin receptor IIB (ActRIIB) ligand trap ...  KER-065 is designed to bind and inhibit activin A and myostatin to. ... KER-065 ... KER-065. ... KER-065 1.0 mg/kg.
  • 1
×